Paper Details

  1. Home
  2. Paper Details

Antitumor and antimetastatic effects of dacarbazine combined with cyclophosphamide and interleukin-2 in Lewis lung carcinoma (3LL).

Author: BonmassarE, LeonettiC, LozuponeF, TentoriL

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

The study found that both dacarbazine (DTIC) and cyclophosphamide (CY) significantly reduced tumor growth and metastases in mice with Lewis lung carcinoma (3LL). These effects were associated with increased immunogenicity of 3LL cells, making them more susceptible to the immune system. However, the drugs' immunosuppressive effects also reduced the benefits of this immunogenicity. Adding interleukin-2 enhanced the antitumor and antimetastatic activity of the chemotherapeutic regimen.
Paper Details　
Original Abstract of the Article :
The antitumor and antimetastatic activity of dacarbazine (DTIC) alone or in combination with cyclophosphamide (CY) was tested in C57BL/6 mice bearing Lewis lung carcinoma (3LL). Treatment with both agents significantly reduced tumor growth and the number of metastases. These effects were associated ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/BF01526557

データ提供：米国国立医学図書館（NLM）

A Combined Approach to Fighting Cancer: Dacarbazine, Cyclophosphamide, and Interleukin-2

The field of cancer research is always searching for more effective treatment strategies. This research investigates the use of dacarbazine combined with cyclophosphamide and interleukin-2, a combination of chemotherapy and immunotherapy, to treat Lewis lung carcinoma (3LL) in mice. The researchers tested the efficacy of this combination against tumor growth and metastasis.

A Powerful Alliance Against Cancer

This study found that the combination of dacarbazine and cyclophosphamide significantly reduced tumor growth and the number of metastases in mice with Lewis lung carcinoma. The addition of interleukin-2 further enhanced this effect, suggesting that combining chemotherapy and immunotherapy could be a potent strategy against cancer.

Harnessing the Power of the Immune System

This research highlights the potential of combining chemotherapy and immunotherapy to fight cancer. By targeting both the tumor directly and boosting the immune system's ability to fight cancer cells, this combined approach could lead to more effective treatments and improved outcomes for patients.

Dr.Camel's Conclusion

Imagine a camel caravan encountering a sandstorm. The caravan needs to work together, using both strength and resilience, to overcome the storm. Similarly, fighting cancer requires a multi-pronged approach, combining chemotherapy and immunotherapy, like a strong and resilient caravan.

Date :
  1. Date Completed 1996-07-05
  2. Date Revised 2019-09-09
Further Info :

Pubmed ID

8635195

DOI: Digital Object Identifier

10.1007/BF01526557

Related Literature

Article Analysis
・Effects of dacarbazine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.